comparison of two local anaesthetics in supraclavicular brachial plexus block in forearm and hand surgeries .
Phase 4
Completed
- Conditions
- Health Condition 1: null- 60 patients of either sex of ASA class 1 or 2 posted for upper limb surgery under supraclavicular brachial plexus block
- Registration Number
- CTRI/2018/03/012750
- Lead Sponsor
- Department of Anaesthesia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
60 patients of either sex of ASA class 1 or 2
Exclusion Criteria
History of respiratory ,cardiac ,hepatic or renal disease,pregnant women, any history of bleeding disorders,local infection at the site of injection,patient sensitive or allergic to bupivacaine or ropivacaine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean duration of onset of sensory and motor block <br/ ><br> Mean Duration of analgesiaTimepoint: single
- Secondary Outcome Measures
Name Time Method quality of anaesthesia between two groups. <br/ ><br>Any side effects of ropivacaine and bupivacaineTimepoint: Single
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ropivacaine and bupivacaine sodium channel blockade in brachial plexus blocks (CTRI/2018/03/012750)?
How does 0.5% ropivacaine compare to 0.5% bupivacaine in efficacy and safety for supraclavicular brachial plexus block in forearm/hand surgeries?
Which biomarkers predict differential response to ropivacaine versus bupivacaine in ASA 1/2 patients undergoing upper limb surgery?
What adverse events are associated with 0.5% ropivacaine versus 0.5% bupivacaine in brachial plexus blocks and their management strategies?
Are there combination approaches with adjuvants like epinephrine or clonidine that enhance analgesic duration of ropivacaine and bupivacaine in brachial plexus blocks?